A
Anil Chandraker
Researcher at Brigham and Women's Hospital
Publications - 225
Citations - 11075
Anil Chandraker is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 51, co-authored 215 publications receiving 9892 citations. Previous affiliations of Anil Chandraker include Lahey Hospital & Medical Center & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection.
Anil Chandraker,H. Azuma,Kari C. Nadeau,Charles B. Carpenter,Nicholas L. Tilney,Wayne W. Hancock,Mohamed H. Sayegh +6 more
TL;DR: The data are the first to demonstrate that blocking T cell-costimulatory activation late after transplantation, after initial graft injury, prevents progression of chronic allograft rejection supporting the hypothesis that ongoing T cell recognition of alloantigen and activation are key mediators of ongoing chronic allogsraft rejection.
Journal ArticleDOI
Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines.
Hilde-Kari Guttormsen,Arlene H. Sharpe,Anil Chandraker,Anne Karin Brigtsen,Mohammed H. Sayegh,Dennis L. Kasper +5 more
TL;DR: It is suggested that MHC class II Ag-TCR, B7-CD28, and CD40-CD40L interactions are critical for immune responses to glycoconjugate vaccines in vivo.
Journal ArticleDOI
CD28-b7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury
Anil Chandraker,Moriatsu Takada,Kari C. Nadeau,Peach Robert J,Nicholas L. Tilney,Mohamed H. Sayegh +5 more
TL;DR: The findings indicate the long-term functional and molecular consequences of experimental cold ischemia/reperfusion injury, and suggest that B7-2 is critical in the development of organ dysfunction following ischemic injury, even in the absence of alloantigen.
Journal ArticleDOI
The Management of Antibody‐Mediated Rejection in the First Presensitized Recipient of a Full‐Face Allotransplant
Anil Chandraker,Ramon Arscott,George F. Murphy,Christine G. Lian,Ericka M. Bueno,Francisco M. Marty,Helmut G. Rennke,Edgar L. Milford,Stefan G. Tullius,Bohdan Pomahac +9 more
TL;DR: The findings lend support to the call for an update to the Banff classification of rejection in vascularized composite tissue allotransplantation (VCA) to include AMR, and for further studies to better classify the histology and mechanism of action of AMR in VCA.
Journal ArticleDOI
Evaluation of Fluoroquinolones for the Prevention of BK Viremia after Renal Transplantation
Steven Gabardi,Sushrut S. Waikar,Spencer T. Martin,Keri Roberts,Jie Chen,Lea Borgi,Hussein Sheashaa,Christine Dyer,Sayeed K. Malek,Stefan G. Tullius,Nidyanandh Vadivel,Monica Grafals,Reza Abdi,Nader Najafian,Edgar L. Milford,Anil Chandraker +15 more
TL;DR: A 1-month fluoroquinolone course after transplantation was associated with significantly lower rates of BK viremia at 1 year compared with those with no fluoroquolone.